CF Foundation backs a new round for a biotech upstart out to rival the mighty Vertex
As a postdoc fellow in 1989, Batsheva Kerem was part of the dogged team that worked with current NIH director Francis Collins to identify the faulty gene behind cystic fibrosis. Now, more than three decades later, she’s leading one company’s efforts to alter a key mutation in that gene — and she just got $28.5 million to do it.
On Thursday morning, Jerusalem-based SpliSense took the wraps off a Series B round to bring its antisense oligonucleotide (ASO) therapy into the clinic. The round includes up to $8.4 million from the Cystic Fibrosis Foundation, bringing SpliSense’s total raise to just over $30 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.